APA (7th ed.) Citation

Ollier, L., Monte, A. D., Thibault, V., Pugliese, P., Chirio, D., Durant, J., . . . Naqvi, A. (2025). To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation? Open Forum Infectious Diseases, 12(6), 1. https://doi.org/10.1093/ofid/ofaf266

Chicago Style (17th ed.) Citation

Ollier, Laurence, Anne De Monte, Vincent Thibault, Pascal Pugliese, David Chirio, Jacques Durant, Michel Carles, and Alissa Naqvi. "To Switch or Not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?" Open Forum Infectious Diseases 12, no. 6 (2025): 1. https://doi.org/10.1093/ofid/ofaf266.

MLA (9th ed.) Citation

Ollier, Laurence, et al. "To Switch or Not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?" Open Forum Infectious Diseases, vol. 12, no. 6, 2025, p. 1, https://doi.org/10.1093/ofid/ofaf266.